期刊文献+

盐酸左氧氟沙星耳用温敏凝胶的制备及滞留性考察 被引量:6

Study on preparation and stagnation of the levofloxacin hydrochloride ear thermosensitive gels
原文传递
导出
摘要 目的:制备盐酸左氧氟沙星耳用温敏凝胶,并考察其在耳道内的滞留效果。方法:冷法制备盐酸左氧氟沙星耳用温敏凝胶,均匀设计法拟合回归方程,优化P407和P188浓度比例,采用耳道内窥镜和核磁共振成像分别从直观视觉和影像学角度考察其在兔耳道的形态与滞留时间。结果:回归方程为:y=95.6-307x(1)+141x(2),其中x(1)、x(2)分别是P407和P188浓度,选取浓度P407/P188=24%/5%制成盐酸左氧氟沙星温敏凝胶;耳道内窥镜与核磁共振表明本凝胶在兔耳道内迅速发生了相转变,粘附于耳道内,滞留时间超过8 h。结论:制备的盐酸左氧氟沙星耳用温敏凝胶能延长药物在耳道内的滞留时间,达到缓释效果,减少用药次数。 OBJECTIVE To prepare the levofloxacin hydrochloride ear thermosensitive gels and investigate the stagnation in the ear canal.METHODS The levofloxacin hydrochloride ear thermosensitive gels were prepared by cold method.The regression equation was established and the concentration of P407 and P188 were optimized by uniform design.The stagnation of the thermosensitive gels in the rabbit ears were investigated by ear endoscope and Magnetic Resonance Imaging(MRI) respectively.RESULTS The regression equation was y=95.6-307x(1)+141x(2).The optimized concentration of P407/P188 was 24%/5%.It was proved that the levofloxacin hydrochloride ear thermosensitive gels turned into gelation quickly and stayed in the ear over 8 hours.CONCLUSION The levofloxacin hydrochloride ear thermosensitive gels improve the stagnation in ears,slow the release of the drug and reduce the times of usage.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2012年第19期1520-1522,共3页 Chinese Journal of Hospital Pharmacy
关键词 盐酸左氧氟沙星 温敏凝胶 泊洛沙姆 滞留性 levofloxacin hydrochloride thermosensitive gels poloxamer stagnation
  • 相关文献

参考文献7

二级参考文献99

共引文献170

同被引文献70

  • 1李娅杰,刘瑄.泪液中药物浓度检测的意义[J].中国临床药理学杂志,2006,22(5):397-398. 被引量:4
  • 2陶涛,赵雁,岳鹏,董文心,陈庆华.石杉碱甲鼻用原位凝胶的制备及其经鼻脑靶向性评价[J].药学学报,2006,41(11):1104-1110. 被引量:35
  • 3杨义芳,孔德云.中药提取分离手册[M].北京:化学工业出版社,2008.
  • 4章永望,赵会英,张娜.新型可注射温敏水凝胶的制备及其释药性能[J].北京化工大学学报(自然科学版),2007,34(5):535-539. 被引量:9
  • 5Wollstein G, Kagemann L, Bilonick R A, et al. Retinal nerve fibre layer and visual function loss in glaucoma:the tipping point[J]. Br J Ophthalmol, 2012, 96(1):47-52.
  • 6Attebo K. The medical therapies for chronic glaucoma[J]. Medicine Today, 2012, 4(07).
  • 7M enp J, Volotinen-Maja M, Kautiainen H, et al. Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops[J]. Drug Metab Dispos, 2014, 42(12):2068-2076.
  • 8Peeters A, Schouten J S A G, Severens J L, et al. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension[J]. Acta ophthalmologica, 2012, 90(2):146-154.
  • 9Goldberg I, Pina R G, Lanzagorta-Aresti A, et al. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension:a 12-week randomised controlled trial[J]. Br J Ophthalmol, 2014, 98(7):926-931.
  • 10Akash M S H, Rehman K, Sun H, et al. Assessment of release kinetics, stability and polymer interaction of poloxamer 407-based thermosensitive gel of interleukin-1 receptor antagonist[J]. Pharm Dev Technol, 2013, 19(3):278-284.

引证文献6

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部